Study Finds Immunoglobulin Therapy Fails to Prevent Hospitalizations in CLL, Raising Treatment

A large-scale, real-world study published in Blood Advances challenges the long-held assumption that regular immunoglobulin replacement therapy (IgRT) effectively prevents serious infections in patients with chronic lymphocytic leukemia (CLL). The research found that despite its growing use, IgRT was not associated with a reduced risk of infection-related hospitalizations, prompting calls for a re-evaluation of its use.

Patients with CLL often have a compromised immune system due to the disease, leading to a deficiency in antibodies, a condition known as hypogammaglobulinemia. IgRT has been a standard treatment to provide these patients with donor-derived antibodies to help them fight infections. However, this study is the first to analyze a large, real-world cohort over a long period (14 years) to assess its true prophylactic benefit.

The study, which included data from over 6,200 patients, revealed several concerning trends:

Ineffective Prophylaxis: The research found no link between regular IgRT use and a lower risk of hospitalization for infections. This suggests that the therapy may not be as effective in preventing serious infections as previously believed.
Reactive, Not Proactive: The data showed a strong correlation between a recent serious infection and the initiation of IgRT. This indicates that the therapy is often used reactively to a health crisis rather than proactively to prevent one. The authors noted that patients with a serious infection were about 75 times more likely to start IgRT than those without.
Rising Use, Rising Infections: Despite a fourfold increase in IgRT use over the study period, the rate of serious infections among CLL patients still doubled. This finding directly questions the effectiveness of the therapy in a real-world setting.
Mortality and Cost Concerns: The study found that serious infections were a major driver of mortality, and IgRT did not appear to improve survival. This, combined with the therapy’s high cost and limited global supply, led authors to urge for a critical review of when and for how long patients should be on this treatment.

The study’s findings are a crucial step toward more targeted and evidence-based strategies for managing infections in CLL, ensuring that patients receive treatments that provide a tangible benefit.